A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Abstract Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal ne...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Maximilian Mastall, Patrick Roth, Andrea Bink, Angela Fischer Maranta, Heinz Läubli, Andreas Felix Hottinger, Thomas Hundsberger, Denis Migliorini, Adrian Ochsenbein, Katharina Seystahl, Lukas Imbach, Tibor Hortobagyi, Leonhard Held, Michael Weller, Hans-Georg Wirsching
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2024-01-01
سلاسل:	BMC Cancer
الموضوعات:	Epilepsy Gabapentin Sulfasalazine Memantine Cancer neuroscience
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12885-023-11797-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!